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The clot thickens
AB Fogo1
Vascular sclerosis has been linked to many risk factors, including 
smoking, family history, low birth weight, and hypertension. In 
interesting studies, Goforth et al. show an increased rate of mutations 
in thrombophilic molecules in patients with vascular sclerosis in renal 
biopsies, suggesting yet another mechanism.
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epitopes. Th at a moderate overexpression 
of the receptor in macula densa cells is 
responsible for a signifi cant increase of 
COX-2 expression again suggests an 
extremely tight control of the eff ects of 
receptor activation in basal states.
Th ere is an increasing interest in the 
(pro)renin receptor, probably because 
it provides now a functional role for 
prorenin that was suspected long ago. 
The mechanism of control of recep-
tor expression and desensitization is 
unknown so far. Th e elucidation of the 
molecular basis of the control of recep-
tor activation in normal tissue, the study 
of the degree of receptor expression 
in pathological states, and the conse-
quences of receptor overactivation now 
merit attention, and these studies would 
undoubtedly improve our knowledge of 
the tissue renin–angiotensin system.
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Th e etiology and pathogenesis of vas-
cular sclerosis have remained obscure, 
despite multiple levels of investigation. 
Th ese studies have examined a variety of 
possible factors, including smoking, obe-
sity, family history, and even low birth 
weight. A major focus has been on the 
well-known link between hypertension 
and accelerated vascular disease. How-
ever, vascular sclerotic lesions did not 
correlate with extent of hypertension in a 
biopsy study of presumed arterionephro-
sclerosis in African Americans.1 Further, 
the extent of sclerosis of arterioles and 
arteries did not correlate with the extent 
of global glomerulosclerosis. In a retro-
spective study examining biopsies done 
for clinical indications, vascular sclerosis 
and glomerulosclerosis were more severe 
in African Americans than in whites.2 
However, in neither population was 
mean arterial pressure predictive of these 
morphologic lesions. In a large review of 
renal biopsies, Meyrier et al. found that 
degree of vascular sclerosis did not corre-
late with hypertension, and surprisingly, 
vascular sclerosis was even present at 
moderately severe levels in tubulointer-
stitial disease processes.3 Further, not all 
patients who exhibit hypertension show 
signifi cant vascular lesions, particularly 
in the white population.4
These findings have pointed to the 
possibility of unrecognized factors 
other than blood pressure accounting 
for sclerosis of the vasculature. In the 
interesting study by Goforth et al.5 (this 
issue), the possibility of contribution of 
inherited thrombophilia to vascular 
sclerosis was investigated. Th ey studied 
renal biopsies in adult patients with vas-
cular sclerotic lesions, defi ned morpho-
logically by intimal fi brosis and medial 
hypertrophy, excluding cases of immune 
complex glomerulonephritis. Patients 
were then further categorized as those 
with diabetes, hypertension, or both, 
those who smoked, and, fi nally, those 
with vascular sclerosis of unknown eti-
ology. Genomic DNA extracted from 
remaining frozen tissue from these 
biopsies was then investigated to iden-
tify any mutations in the gene for factor 
V or for prothrombin, or mutation in a 
gene that causes hyperhomocysteinemia 
(methylenetetrahydrofolate reductase, 
MTHFR). Interestingly, among patients 
without known risk factors for vascular 
disease, such as diabetes, hypertension, 
or smoking, a signifi cant proportion had 
mutations in one or more of these three 
genes. Th e small sample size precludes 
broad conclusions regarding other 
populations. However, the clustering of 
mutations in about half of the previously 
considered idiopathic vascular sclerosis 
group is of great interest.
Th e contribution of factors govern-
ing hemostasis to acute thrombotic 
lesions and also vascular sclerosis has 
previously been recognized. Th us, plas-
minogen activator inhibitor-1 (PAI-1) 
is associated with increased risk for 
cardiovascular and renal disease.6,7 
PAI-1 levels are also regulated at the 
genetic level, with polymorphic variance 
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infl uencing plasma levels. Th e 4G/4G 
variant is associated with higher plasma 
PAI-1 levels than the 5G/5G variant; pre-
sumably this is related to the binding of 
4G to a transcription activator and of 5G 
to an additional transcription repressor.8 
Diabetic patients homozygous for 4G 
had increased macro- and microvascular 
complications, particularly when they 
were also homozygous for the D geno-
type of angiotensin-converting enzyme, 
which is associated with increased renin–
angiotensin system activity.9 As dis-
cussed by Goforth et al.,5 numerous 
additional factors, such as the comple-
ment-regulatory molecule factor H, 
and the coagulation cascade modifi ers 
protein C, protein S, and anti-thrombin 
III, could also contribute to risk not only 
for thrombosis, but for subsequent vas-
cular sclerosis.
Th e link forged between prothrom-
botic factors and sclerosis may be direct, 
as is the case with PAI-1 (Figure 1). 
PAI-1 has several actions. It not only 
directly inhibits breakdown of fibrin 
by inhibiting formation of plasmin but 
also inhibits proteolysis by plasmin and 
plasminogen activators and other prote-
olytic molecules, thus promoting fi bro-
sis and sclerosis. PAI-1 has, in addition, 
plasmin-independent eff ects to promote 
cell migration and fi brosis.6,7 For other 
molecules, the link may be indirect (Fig-
ure 1). Inherited thrombophilias may 
have adverse infl uence on pregnancy 
outcomes.10 Whether they also could 
have more subtle eff ects on fetal develop-
ment and growth and contribute to low 
birth weight, with subsequent increased 
risk for renal and cardiovascular disease, 
is not known. Another indirect link 
between thrombosis and sclerosis could 
be mediated by initial subtle endothelial 
dysfunction with or without localized 
thrombosis chronically resulting in a 
fi brotic reaction. Indeed, in the study 
by Goforth et al.,5 the latter mechanism 
is suggested in some patients by the 
electron microscopic fi ndings demon-
strating subendothelial expansion and 
new glomerular basement membrane 
formation, resulting in double contours, 
the classic morphologic appearance of 
a chronic thrombotic microangiopathy. 
Th e study by Goforth et al.5 importantly 
extends our previous observations link-
ing such morphologic fi ndings to a pre-
vious overt thrombotic condition or 
malignant hypertension, to patients in 
whom such underlying conditions were 
not clinically apparent and in whom no 
hypertension was yet present. In such 
patients, the results of Goforth et al.5 
suggest that genetic factors modulating 
thrombosis have infl uenced the develop-
ment of vascular sclerosis. Whether the 
increased mutation rate of hemostatic 
factors also is present in other patient 
populations, such as African Americans, 
remains to be determined.
The morphologic detection of vas-
cular sclerosis, even in the absence of 
hypertension, may be an ominous sign 
for progressive renal dysfunction, in 
that compliance and reactivity of ves-
sels may be compromised when the 
structure of the vessel is thus modifi ed. 
Whether treatment specifi cally aimed 
at modifying activity of thrombophilic 
factors, rather than at decreasing blood 
pressure, would be particularly effica-
cious in ameliorating vascular scle-
rosis in this newly identified patient 
group, remains to be seen. Specific 
recognition of molecular defects con-
tributing to vascular injury provides 
exciting new targets for treatment 
and intervention.
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Figure 1 | Proposed schema for hypothesized mechanisms of interactions between 
thrombophilia and vascular sclerosis. Thrombophilia may promote sclerosis directly by 
organization of thrombotic microangiopathic injury, or perhaps indirectly by resulting in adverse 
pregnancy outcomes, such as low birth weight, which has been linked to increased cardiovascular 
disease. Other factors influencing thrombosis, such as PAI-1, plasminogen activator inhibitor-1 
(PAI-1), have direct effects to promote sclerosis by inhibiting breakdown of extracellular matrix and 
preventing clot lysis.
